Low-Dose Trazodone for Symptomatic Patients With Esophageal Contraction Abnormalities: A Double-Blind, Placebo-Controlled Trial

Ray E. Clouse, Patrick J. Lustman, Thomas C. Eckert, David M. Ferney, Linda S. Griffith

Research output: Contribution to journalArticlepeer-review

288 Scopus citations

Abstract

Twenty-nine patients with esophageal symptoms and contraction abnormalities of the esophageal body completed a 6-wk, double-blind, placebocontrolled trial of trazodone (100–150 mg1day). Measures of esophageal and psychologic symptoms were completed at entry and at each follow-up visit. Esophageal manometry was repeated at the termination of the trial. Upon completion of the treatment, patients receiving trazodone (n = 15) reported a significantly greater global improvement than those receiving placebo (n =14; p = 0.02). Although a variable clinical response was observed, the trazodone group had less residual distress over esophageal symptoms compared with the placebo group (59% ± 9% vs. 108% ± 19%, p = 0.03). Manometric changes observed during the course of the trial were not influenced by treatment nor by clinical response. Remarkable reductions in ratings of chest pain were reported by both treatment groups, emphasizing the importace of controlled trials when studying this patient population. We conclude that low-dose trazodone therapy can be of benefit in the management of symptomatic patients with esophageal contraction abnormalities. In addition, our findings support recent observations that manometric abnormalities characterizing this patient group may not be solely responsible for symptoms.

Original languageEnglish
Pages (from-to)1027-1036
Number of pages10
JournalGastroenterology
Volume92
Issue number4
DOIs
StatePublished - 1987

Fingerprint

Dive into the research topics of 'Low-Dose Trazodone for Symptomatic Patients With Esophageal Contraction Abnormalities: A Double-Blind, Placebo-Controlled Trial'. Together they form a unique fingerprint.

Cite this